375 related articles for article (PubMed ID: 33928479)
1. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
4. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
5. Kidney volume and function in autosomal dominant polycystic kidney disease.
Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
[TBL] [Abstract][Full Text] [Related]
6. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
[TBL] [Abstract][Full Text] [Related]
8. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease.
Tokiwa S; Muto S; China T; Horie S
Clin Exp Nephrol; 2011 Aug; 15(4):539-45. PubMed ID: 21431900
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
10. The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease.
Ferraro PM; Bargagli M; Faller N; Anderegg MA; Huynh-Do U; Vogt B; Gambaro G; Fuster DG
J Nephrol; 2023 May; 36(4):1011-1018. PubMed ID: 36528688
[TBL] [Abstract][Full Text] [Related]
11. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
13. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
[TBL] [Abstract][Full Text] [Related]
14. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
15. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.
Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM
Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443
[TBL] [Abstract][Full Text] [Related]
16. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
Girardat-Rotar L; Puhan MA; Braun J; Serra AL
J Nephrol; 2018 Feb; 31(1):87-94. PubMed ID: 28386880
[TBL] [Abstract][Full Text] [Related]
18. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
19. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; You Z; Gitomer B; Brosnahan G; Torres VE; Chapman AB; Perrone RD; Steinman TI; Abebe KZ; Rahbari-Oskoui FF; Yu ASL; Harris PC; Bae KT; Hogan M; Miskulin D; Chonchol M
J Am Soc Nephrol; 2018 Feb; 29(2):571-578. PubMed ID: 29118087
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]